MarketVIEW: CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary

  • ID: 4455641
  • Report
  • 110 Pages
  • iOnco-analytics
1 of 4
Details the Disease Background, Epidemiology of the Disease, Current Therapies and Treatment Options, and Novel Immunotherapies With a Focus on CAR-T

FEATURED COMPANIES

  • Autolus Ltd
  • Bluebird Therapeutics
  • Celyad
  • Gilead
  • Juno Therapeutics, Inc.
  • Legend Biotech
  • MORE

Multiple myeloma is a cancer that develops from the plasma cells of the bone marrow and accounts for ~1% of all cancers and ~10% of all hematological malignancies. US estimates for multiple myeloma incidence in 2017 are >30,000 new cases diagnosed and approximately 12,500 deaths. The age adjusted incidence in the US is ~ 4 per 100,000 and, in the UK the value is ~9 per 100,000. The worldwide incidence of multiple myeloma was >114,000 new cases in 2012.

Despite significant improvements in treatments including the use of immunomodulatory drugs (e.g. lenalidomide, pomalidomide) and proteasome inhibitors (e.g. bortezomib, carfilzomib, ixazomib) in the first line setting, and the recent approvals for histone deacetylase inhibitors (e.g. panobinostat) and monoclonal antibodies (daratumumab and elotuzumab), most patients eventually relapse or are refractory and the management of the disease remains challenging.

Novel immunotherapeutic approaches in the treatment of multiple myeloma include checkpoint inhibitors, monoclonal antibodies,  vaccines and adoptive T-cell therapies. Chimeric Antigen Receptor (CAR-T) approaches are also being investigated by several companies including Novartis, Kite/Gilead, Juno Therapeutics/Celgene, Bluebird therapeutics/Celgene, Legend Biotech/J&J as well as several companies in early stage clinical investigations (Autolus, Poseida Therapeutics, Celyad).  
 
This MarketVIEW product consists of a comprehensive Executive presentation (~110 slides, .pdf) detailing the disease background, epidemiology of the disease, current therapies and treatment options, and novel immunotherapies with a focus on CAR-T. Also included is a summary and analysis of published and registered ongoing CAR-T clinical studies detailing the phases, targets under investigation, study status and summary of study protocols (patient numbers, dosing, study objectives). Key significant data available to date is discussed in further detail.  122 references are cited in this work.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Autolus Ltd
  • Bluebird Therapeutics
  • Celyad
  • Gilead
  • Juno Therapeutics, Inc.
  • Legend Biotech
  • MORE

Executive summary

Multiple Myeloma - Disease background and risk factors

  • Multiple myeloma: background
  • Plasma cell disorders and multiple myeloma
  • Amyloidosis Associated With Plasma Cell Neoplasms
  • Multiple myeloma and plasma cell disorders
  • Multiple myeloma Immunoglobulin (IG) variants
  • Multiple myeloma: molecular subtypes and oncogenes
  • Multiple myeloma: risk factors

Multiple Myeloma - Diagnosis, symptoms, staging and prognosis

  • Multiple myeloma: diagnosis, staging and prognosis
  • Multiple myeloma: diagnosis and prognosis
  • Multiple myeloma: staging
  • Multiple myeloma: recommended tests
  • Multiple myeloma: symptoms

Multiple Myeloma - Epidemiology

  • Multiple myeloma: World incidence and mortality rates by region and sex
  • Multiple myeloma: overall statistics in the US
  • Multiple myeloma: new cases and deaths US
  • Multiple myeloma: estimated incidence versus other cancer types in US 2017
  • Multiple myeloma: US incidence and death rate by age
  • Multiple myeloma: US incidence by sex and race/ethnicity
  • Multiple myeloma: US death rate by sex and race/ethnicity
  • Multiple myeloma: US new cases and deaths 1975-2014 and five year survival
  • Multiple myeloma: overall statistics UK
  • Multiple myeloma: UK new cases and incidence rates by country (2014)
  • Multiple myeloma: UK average number of new cases and age-specific incidence rates by age (2012-2014)
  • Multiple myeloma: UK incidence and mortality rates over time
  • Multiple myeloma: UK number of deaths and mortality rate by country and sex (2014)
  • Multiple myeloma: incidence projections to 2035
  • Multiple myeloma: mortality projections to 2035
  • Multiple myeloma: UK prevalence statistics
  • Multiple myeloma: European incidence by sex (2012)
  • Multiple myeloma: European mortality by sex (2012)
  • Multiple myeloma: Prevalence in Europe both sexes 2012
  • Multiple myeloma: Prevalence in Europe by sex 2012
  • Multiple myeloma: Canada- incidence and mortality statistics, 2012
  • Multiple myeloma: Canada-prevalence statistics, 2012
  • Multiple myeloma: Japan-incidence and mortality statistics, 2012
  • Multiple myeloma: Japan-prevalence statistics, 2012
  • Multiple myeloma: Australia-incidence and mortality statistics, 2012
  • Multiple myeloma: Australia-prevalence statistics, 2012
  • Multiple myeloma: Incidence and mortality comparison- US, Canada, Europe, Japan, Australia in 2012

Multiple Myeloma - Treatment and unmet need

  • Multiple myeloma: treatment
  • Multiple myeloma: treatment (transplant-eligible patients)
  • Multiple myeloma: treatment (transplant-ineligible patients)
  • Multiple myeloma: treatment of relapsed and refractory disease
  • Multiple myeloma: unmet need

Novel treatments for Multiple Myeloma - Immunotherapy approaches

  • Multiple myeloma: immunotherapies
  • Chimeric Antigen Receptor T cells (CAR-T) - overview
  • Chimeric Antigen Receptor T cells (CAR-T) - antigen selection
  • CAR-T cell therapy: potential issues and challenges
  • Steps in the manufacture of a CAR-T cell therapy
  • Multiple Myeloma targets for CAR-T cell therapy
  • CAR-T cell therapy for Multiple Myeloma - Published clinical studies
  • Pipeline analysis table: CAR-T studies for multiple myeloma on clinicaltrials.gov
  • Pipeline analysis: Summary
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting CD138: Chinese PLA General Hospital
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting CD19: U. Penn/Novartis
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: National Cancer Institute
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: U. Penn/Novartis
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: Nanjing Legend Biotech Co./J&J
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: MSKCC, Fred Hutch, Juno Therapeutics, Inc.
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: Autolus Ltd
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: Bluebird Bio/Celgene
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: Kite/Gilead
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting BCMA: Poseida Therapeutics
  • Pipeline analysis: Key multiple myeloma CAR-T clinical studies targeting NKG2D Receptor CAR-T: Celyad

Bibliography

About the Publisher

Disclaimer

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Autolus Ltd
  • Bluebird Bio
  • Bluebird Therapeutics
  • Celgene
  • Celyad
  • Chinese PLA General Hospital
  • Fred Hutch
  • Gilead
  • J&J Autolus
  • Juno Therapeutics, Inc.
  • Kite
  • Legend Biotech
  • MSKCC
  • Nanjing Legend Biotech Co.
  • National Cancer Institute
  • Novartis
  • Poseida Therapeutics
  • U. Penn
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll